Targeting Tools: Targeting the Dopamine Transporter

Advanced Targeting Systems announces the availability of two monoclonal antibodies to the dopamine transporter (DAT). These antibodies have become a standard for work on DAT and have already played a prominent role in the characterization of the dopamine transporter. The two antibodies are rat monoclonals, so they can be excellent for multiple staining protocols. Anti-DAT-NT, Cat. […]

Targeting Tools: Targeting the Dopamine Transporter Read More »

Substance P-Saporin (SP-SAP) Drug Development Update

Substance P-Saporin (SP-SAP) is under development as a chronic pain therapeutic with tremendous potential to permanently eliminate suffering in many painful diseases and conditions. ATS is awaiting news from the National Institutes of Health on further funding to fulfill FDA requirements to bring SP-SAP to clinical trial in humans. ATS has a patent on SP-SAP

Substance P-Saporin (SP-SAP) Drug Development Update Read More »

Cover Article: A New Immunotoxin for Targeting Dopaminergic Neurons

Dopaminergic neurons are widely studied because of their role in one of the devastating diseases of old age, Parkinson’s. Lesioning studies using 6-hydroxydopamine or MPTP have been useful in research on Parkinson’s Disease. However, these reagents have limitations such as MPTP affecting catecholaminergic neurons and 6-OHDA stability and specificity issues. Targeting dopaminergic neurons with an

Cover Article: A New Immunotoxin for Targeting Dopaminergic Neurons Read More »

Funding Awarded for SBIR Phase II Grant

On February 1, 2003 ATS was awarded an $800,000 grant from the National Institutes of Health, National Institute of Mental Health. This three-year grant will support the creation of monoclonal antibodies to the extracellular domains of G protein-coupled receptors. These receptors play an important role in all aspects of human health, reflecting their widespread presence

Funding Awarded for SBIR Phase II Grant Read More »

Cover Article: Biotinylated targeting. A viable option?

For the IB4-SAP (Cat. #IT-10) illustration (Figure 1), our thanks to Christopher N. Honda, Ph.D., Associate Professor, Department of Neuroscience, University ofMinnesota, 6-145 Jackson Hall, 321 Church Street, Minneapolis, MN 55455 This issue of our quarterly newsletter addresses the use of biotinylated materials in targeting. ATS is now offering a biotinylation service (see p. 7)

Cover Article: Biotinylated targeting. A viable option? Read More »

SP-SAP as a Chronic Pain Therapeutic: An Update

Advanced Targeting Systems continues to search for funding to develop Substance P-Saporin (SP-SAP) as a chronic pain therapeutic. In May of last year we decided to seek venture capital funding and began traveling to make presentations to potential investors. The response from most everyone we spoke to was positive and they thought the potential of

SP-SAP as a Chronic Pain Therapeutic: An Update Read More »

Cover Article: Deep Lumbar Neurons Control Ejaculation

Contributed by William Truitt, PhD, Department of Cell Biology, Neurobiology, and Anatomy, Neuroscience Graduate Program, University of Cincinnati, College of Medicine, Post Office Box 670521, Cincinnati, OH 45267-0521, USA. Previously we demonstrated the existence of a spinothalamic pathway in the male rat where neural activation is specifically induced by ejaculation.1 This pathway includes the parvocellular

Cover Article: Deep Lumbar Neurons Control Ejaculation Read More »

Targeting Trends 2002 Newsletter

Read the 2002 Newsletters and receint scientific references 2002, issue 1: Control Conjugates: The Perfect Companion for Targeted Toxins / by Lappi DA / featuring Control Conjugates SFN Poster of the Year Targeting Talk: Toxin Safety Targeting Tools: Serotonin Transporter Antibody 2002, issue 2: HCRT-SAP Lesion Produces Sleepiness While anti-DBH-SAP Lesion Does Not  / by Blanco-Centurion

Targeting Trends 2002 Newsletter Read More »

Shopping Cart
Scroll to Top